XLXin Liu

Xin Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xin Liu has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Wenyan Zhang

    Department of Infectious Diseases, Infectious Diseases and Pathogen Biology Center, The First Hospital of Jilin University

    2 shared publications
  • Xiao-Fang Yu

    Affiliations: School of Life Sciences, Tianjin University, Tianjin, China, Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Baltimore, MD 21205, United States of America

    2 shared publications
  • Guanchen Liu

    First Hospital of Jilin University, Institute of Virology and AIDS Research, 130061 Changchun, China

    1 shared publication
  • Guo-Yue Lv

    The First Hospital of Jilin University

    1 shared publication
  • Hong Wang

    Institute of Virology and AIDS Research, Center of Infectious Diseases and Pathogen Biology, Key Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, The First Hospital of Jilin University

    1 shared publication
  • Jiaxin Yang

    First Hospital of Jilin University, Institute of Virology and AIDS Research, 130061 Changchun, China

    1 shared publication

Latest Publications

  • Open Access

    Optimization and Characterization of Candidate Strain for Coxsackievirus A16 Inactivated Vaccine

    by Jingliang Li, Guanchen Liu, Xin Liu, Jiaxin Yang, Junliang Chang, Wenyan Zhang, Xiao-Fang Yu

    Coxsackievirus A16 (CA16) and enterovirus 71 (EV71), both of which can cause hand, foot and mouth disease (HFMD), are responsible for large epidemics in Asian and Pacific areas. Although inactivated EV71 vaccines have completed testing in phase III clinical trials in Mainland China, CA16 vaccines are still under development. A Vero cell-based inactivated CA16 vaccine was developed by our group. Screening identified a CA16 vaccine strain (CC024) isolated from HFMD patients, which had broad cross-protective abilities and satisfied all requirements for vaccine production. Identification of the biological characteristics showed that the CA16CC024 strain had the highest titer (107.5 CCID50/mL) in Vero cells, which would benefit the development of an EV71/CA16 divalent vaccine. A potential vaccine manufacturing process was established, including the selection of optimal time for virus harvesting, membrane for diafiltration and concentration, gel-filtration chromatography for the down-stream virus purification and virus inactivation method. Altogether, the analyses suggested that the CC-16, a limiting dilution clone of the CC024 strain, with good genetic stability, high titer and broad-spectrum immunogenicity, would be the best candidate strain for a CA16 inactivated vaccine. Therefore, our study provides valuable information for the development of a Vero cell-based CA16 or EV71-CA16 divalent inactivated vaccine.


  • Open Access

    Requirement of HIV-1 Vif C-terminus for Vif-CBF-β interaction and assembly of CUL5-containing E3 ligase

    by Hong Wang, Guoyue Lv, Xiaohong Zhou, Zhaolong Li, Xin Liu, Xiao-Fang Yu, Wenyan Zhang

    Human immunodeficiency virus type 1 (HIV-1) Vif hijacks an E3 ligase to suppress natural APOBEC3 restriction factors, and core binding factor β (CBF-β) is required for this process. Although an extensive region of Vif spanning most of its N-terminus is known to be critical for binding with CBF-β, involvement of the Vif C-terminus in the interaction with CBF-β has not been fully investigated. Here, through immunoprecipitation analysis of Vif C-terminal truncated mutants of various lengths, we identified that CBF-β binding requires not only certain amino acids (G126A, E134A, Y135A and G138A) in the HCCH region but also the HCCH motif itself, which also affects the Vif-mediated suppression of APOBEC3G/APOBEC3F (A3G/A3F). These mutants still maintained interactions with substrate A3G or A3F as well as other cellular factors ElonginB/C (ELOB/C), indicating that their structures were not functionally affected. Moreover, by determining that the BC box also is necessary for CBF-β interaction in vivo, we speculate that binding to ELOB/C induces conformational changes in Vif, facilitating its interaction with CBF-β and consequent interaction with CUL5. These results provide important information on the assembly of the Vif-CUL5-E3 ubiquitin ligase. Identification of the new binding interface with CBF-β at the C-terminus of HIV-1 Vif also provides novel targets for the development of HIV-1 inhibitors.